Shimadzu (7701) Investor presentation summary

Medium-term management plan strategy

• Targets net sales of ¥680.0B by FY2028 with a CAGR of 6.7%, focusing on life science and semiconductor markets.

• Aims to improve profitability through optimized sales mix, pricing, cost reduction, and overseas expansion, especially in North America and India.

• Plans to accelerate new business creation and expand recurring revenue streams.

• Emphasizes business transformation toward customer-centric solutions and strengthening AI transformation.

• Seeks to enhance governance and human capital management.

Business expansion in the life science market

• Core products support healthcare, infectious disease control, and personalized medicine, with strong presence in Asia.

• Life science market and recurring revenue business expected to grow at a CAGR of 6%, outpacing the overall market.

• Focus on expanding LC and MS systems for R&D and quality control, especially in pharmaceuticals and biopharmaceuticals.

• Introduces AI-driven automation and analytical solutions to enhance operational efficiency and data quality.

• Expands service capabilities, consumables portfolio, and global LabTotal business for end-to-end customer support.

Business expansion in the semiconductor market

• Addresses demand for advanced measurement of smaller features and 3D structures in semiconductors.

• Offers integrated solutions for design, manufacturing, and failure analysis, leveraging Tescan's imaging technologies.

• Strengthens global service network for turbomolecular pumps, maintaining leading market share.

• Develops a Process Intelligence Platform to optimize semiconductor processes through data-driven analysis.

• Combines structural, chemical, and process measurement for comprehensive semiconductor solutions.